People

rosenblum-276x303
Andrew Rosenblum, PhD
National Development and Research Institutes, Inc. - Executive Director
National Development and Research Institutes, Inc. - Director, Institute for Treatment and Services Research
Education
PhD, Psychology, Graduate Center, City University of New York
MA, Psychology, New School for Social Research
BA, Philosophy, Adelphi University
Research Interests
Opioid addiction, Medication assisted treatment, Chronic pain, Behavioral interventions, Technology based interventions
BIO
Andrew Rosenblum is the executive director of National Development and Research Institutes (NDRI), Inc., a not-for-profit research firm that conducts substance use and other bio-behavioral research nationwide and throughout the world.  He also serves as director of NDRI’s Institute for Treatment and Services Research.  His scientific contributions primarily include development and evaluation of psychosocial interventions (including eLearning and eTherapy applications) and prevalence surveys.  Many of his recent studies have focused on chronic pain, prescription opioid misuse, and medication assisted treatment such as methadone and buprenorphine.  He has published more than 100 peer-reviewed articles and has served as principal investigator on several NIDA funded studies.
Projects
Principal Investigator, Facilitating MAT Acceptance & Implementation in Problem Solving & Felony Courts. Active
Publications

Recent

Pouget ER, Fong C, Rosenblum A (2018).
Racial/ethnic differences in prevalence trends for heroin use and non-medical use of prescription opioids among entrants to opioid treatment programs, 2005-2016
Substance Use and Misuse, 53 (2), 290-300. doi: 10.1080/10826084.2017.1334070.

Matusow H, Rosenblum A, Parrino M (2018).
Prescription drug monitoring program utilization among 15 US opioid treatment programs
Journal of Substance Abuse Treatment, 85, 17-20. doi: 10.1016/j.jsat.2017.11.009.

Matusow H, Benoit E, Elliott L, Dunlap E, Rosenblum A (2018).
Challenges to opioid treatment programs after Hurricane Sandy: Patient and provider perspectives on preparation, impact, and recovery
Substance Use and Misuse, 53 (2), 206-219. doi: 10.1080/10826084.2016.1267225.

Guarino H, Fong C, Marsch LA, Acosta MC, Syckes C, Moore SK, Cruciani RA, Portenoy RK, Turk DC, Rosenblum A (2018).
Web-based cognitive behavior therapy for chronic pain patients with aberrant drug-related behavior: Outcomes from a randomized controlled trial
Pain Medicine [Epub 2018 Jan 13]. doi: 10.1093/pm/pnx334.

Pouget ER, Bennett AS, Elliott L, Wolfson-Stofko B, Almenana R, Britton PC, Rosenblum A (2017).
Development of an Opioid-Related Overdose Risk Behavior Scale (ORBS)
Substance Abuse, 38 (3), 239-244. doi: 10.1080/08897077.2017.1282914. PMCID: PMC5522769.


Notable

Rosenblum A, Marsch LA, Joseph H, Portenoy RK (2008).
Opioids and the treatment of chronic pain: Controversies, current status, and future directions
Experimental and Clinical Psychopharmacology, 16 (5), 405-416. doi: 10.1037/a0013628. PMCID: PMC2711509.

Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, Magura S, Haddox JD (2007).
Prescription opioid abuse among enrollees into methadone maintenance treatment
Drug and Alcohol Dependence, 90 (1), 64-71. doi: 10.1016/j.drugalcdep.2007.02.012.

Magura S, Rosenblum A (2001).
Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored
Mount Sinai Journal of Medicine, 68 (1), 62-74. PubMed Abstract.

Dr. Rosenblum's Google Scholar Profile
Selected Press